Business Context and Reporting Period
Silo Pharma, Inc. filed a Current Report on Form 8-K dated January 5, 2020, reporting an event that occurred on January 5, 2021. The Company is a Delaware corporation focused on pharmaceutical research.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of a material agreement rather than a periodic financial report.
Material Changes and Agreements
On January 5, 2021, the Company entered into an investigator-sponsored study agreement with the University of Maryland, Baltimore (UMB). Key terms include:
- Project Scope: A clinical study examining a novel peptide-guided drug delivery approach for multiple sclerosis.
- Objectives: Evaluate if MS-1-displaying liposomes can effectively deliver dexamethasone to the CNS and determine superiority over plain liposomes in inhibiting relapses and progression of EAE.
- Timeline: Project work commences on March 1, 2021, continuing until substantial completion, subject to renewal.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the inherent uncertainties of clinical research. The agreement is subject to renewal upon mutual written consent.
Investor Verification Checklist
- Verify the full text of the Sponsored Research Agreement filed as Exhibit 10.1.
- Confirm the start date of March 1, 2021, for the project work.
- Monitor future filings for updates on the clinical study results regarding MS-1-displaying liposomes.
- Note the discrepancy between the report date (Jan 5, 2020) and the event date (Jan 5, 2021) in the source text.